SCHEMBL3472915

SCHEMBL3472915

O=C(O)CCNC(=O)c1ccc(-c2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.52
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 2/20 0.52
GCG P01275 1/20 0.51
GCGR P47871 10/20 0.49
MAPT P10636 3/20 0.48
CYP2C9 P11712 2/20 0.47
GIPR P48546 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C8 P10632 1/20 0.47
KCNH2 Q12809 1/20 0.47
NR3C2 P08235 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474330 0.90 RXRA (0.54) RXRANR1H2NR1H3MAPTCYP2C9
SCHEMBL3472342 0.90 RXRA (0.54) RXRANR1H2NR1H3GCGRMAPT
SCHEMBL3473769 0.90 RXRA (0.52) RXRANR1H2NR1H3GCGGCGR
SCHEMBL3473364 0.89 RXRA (0.56) RXRANR1H2NR1H3GCGMAPT
SCHEMBL3473854 0.88 RXRA (0.54) RXRANR1H2NR1H3MAPTNR3C2
SCHEMBL3472065 0.87 RXRA (0.57) RXRANR1H2NR1H3MAPTCYP2C9
SCHEMBL15690868 0.87 RXRA (0.55) RXRANR1H2NR1H3MAPTCYP2C9
SCHEMBL3473978 0.87 RXRA (0.53) RXRANR1H2NR1H3MAPTNR3C2
SCHEMBL3470978 0.86 LMNA (0.50) RXRANR1H2NR1H3MAPTCYP2C9
SCHEMBL3475775 0.86 RXRA (0.56) RXRANR1H2NR1H3MAPTNR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.